AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15964147 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 50
Study 15964147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50
Study 15964147 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and Apomorphine
Number of subjects: 50
Study 11923586 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine (900 mg intravenous)
Number of subjects: 58
Study 11923586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 10373342 — intervention group
Group type: EXPERIMENTAL
Intervention: biosynthetic GH 2 IU/m2 s.c. daily (n=13)
Number of subjects: 24
Study 10373342 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=11)
Number of subjects: 24
Study 7756472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (200/75 mg once weekly)
Number of subjects: 533
Study 7756472 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg every 4 weeks)
Number of subjects: 533
Study 7756472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (in tolerant patients)
Number of subjects: 533
Study 7756472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine and aerosolized pentamidine
Number of subjects: 533
Study 2184811 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized normal saline (HNS)
Number of subjects: 60
Study 2184811 — intervention group
Group type: COMPARATOR
Intervention: Heparinized 5% dextrose water (HD5W)
Number of subjects: 60
Study 6158933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast interferon
Number of subjects: 0
Study 6158933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30690418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixel-based analysis of diffusion MRI data
Number of subjects: 221
Study 30690418 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractional anisotropy analysis
Number of subjects: 221
Study 27820729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance
Number of subjects: 26
Study 25886354 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory physical and psychosocial intervention
Number of subjects: 400
Study 25886354 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the intervention in year two
Number of subjects: 400
Study 23899008 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (12 weeks)
Number of subjects: 41
Study 23899008 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 41
Study 21273172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with lenalidomide and dexamethasone
Number of subjects: 212
Study 21273172 — intervention group
Group type: COMPARATOR
Intervention: Discontinued therapy without progression (control group)
Number of subjects: 212
Study 21273172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued lenalidomide treatment
Number of subjects: 212
Study 21273172 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional cycle of lenalidomide
Number of subjects: 212
Study 19586958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic-guided interscalene brachial plexus blockade (ISB)
Number of subjects: 40
Study 19586958 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 40
Study 18410864 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam 8 mg (twice daily)
Number of subjects: 200
Study 18410864 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg (twice daily)
Number of subjects: 200
Study 18410864 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg (twice daily)
Number of subjects: 200
Study 18410864 — intervention group
Group type: EXPERIMENTAL
Intervention: dipyrone 1 g (three times daily)
Number of subjects: 200
Study 18410864 — intervention group
Group type: COMPARATOR
Intervention: placebo (twice daily)
Number of subjects: 200
Study 15980656 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated strategy
Number of subjects: 60
Study 15980656 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-consonant mnemonic strategy
Number of subjects: 60
Study 15980656 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-practice)
Number of subjects: 60
Study 15980656 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning speed (fast learners)
Number of subjects: 60
Study 11884911 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 53
Study 11884911 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 53
Study 10450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (single 400 mg dose)
Number of subjects: 0
Study 10450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (single 500 mg dose)
Number of subjects: 0
Study 10450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel (single dose 12.5 mg/kg bodyweight)
Number of subjects: 0
Study 10450449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8572849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg/day)
Number of subjects: 54
Study 8572849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 54
Study 2467982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice a day for 4 days
Number of subjects: 13
Study 407607 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 16
Study 407607 — intervention group
Group type: EXPERIMENTAL
Intervention: l-amphetamine
Number of subjects: 16
Study 407607 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 16
Study 407607 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 30638766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pre-test genetic counseling (20-minute presentation via email prior to telephone call)
Number of subjects: 382
Study 30638766 — intervention group
Group type: COMPARATOR
Intervention: Traditional pre-test genetic counseling (in-person)
Number of subjects: 382
Study 28315319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN‐α2a
Number of subjects: 48
Study 28315319 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 48
Study 28315319 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study 25788164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 1190
Study 25788164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1190
Study 23266342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular MVA85A
Number of subjects: 24
Study 23266342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal MVA85A
Number of subjects: 24
Study 23266342 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both routes
Number of subjects: 24
Study 21923715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine granules (3 g/day, 3 g once daily or 1 g three times daily)
Number of subjects: 705
Study 21923715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine granules (3 g/day)
Number of subjects: 705
Study 21923715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine granules (once daily)
Number of subjects: 705
Study 21923715 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day, 1 g three times daily)
Number of subjects: 705
Study 21923715 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day)
Number of subjects: 705
Study 20027354 — intervention group
Group type: EXPERIMENTAL
Intervention: Afala
Number of subjects: 0
Study 20027354 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens extract (reference preparation)
Number of subjects: 0
Study 17099030 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin solution with oral ciprofloxacin
Number of subjects: 53
Study 17099030 — intervention group
Group type: COMPARATOR
Intervention: Placebo with oral ciprofloxacin
Number of subjects: 53
Study 14768081 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane (0.1 mm thickness)
Number of subjects: 62
Study 14768081 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 62
Study 14768081 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane
Number of subjects: 62
Study 11207084 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation of accessory pathways
Number of subjects: 116
Study 11207084 — intervention group
Group type: COMPARATOR
Intervention: Control group of 100 consecutive patients with successful accessory pathway ablation without prior evidence of paroxysmal atrial fibrillation
Number of subjects: 116
Study 9234042 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes with 3.5% THC
Number of subjects: 6
Study 9234042 — intervention group
Group type: COMPARATOR
Intervention: Marijuana cigarettes with 0.0% THC
Number of subjects: 6
Study 9234042 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes with 2.0% THC
Number of subjects: 6
Study 10147265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 1637
Study 10147265 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 1637
Study 3227053 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg (single dose)
Number of subjects: 8
Study 3227053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram 0.75 mg (multiple dosing every 8 hours for 5 days)
Number of subjects: 8
Study 3227053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram 1.5 mg (multiple dosing every 8 hours for 5 days)
Number of subjects: 8
Study 3227053 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (single dose)
Number of subjects: 8
Study 31853772 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to free HIV self‐testing (ST) kits
Number of subjects: 272
Study 31853772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 30621517 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 79
Study 30621517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 28081044 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Partner-related barriers
Number of subjects: 600
Study 28081044 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Sensation-related barriers
Number of subjects: 600
Study 28081044 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Motivation-related barriers
Number of subjects: 600
Study 26305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based cognitive training intervention
Number of subjects: 59
Study 26305186 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control condition
Number of subjects: 59
Study 23368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention for youth depression through primary care
Number of subjects: 0
Study 23368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline depressive symptoms
Number of subjects: 0
Study 23368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline problematic substance use
Number of subjects: 0
Study 21401351 — intervention group
Group type: COMPARATOR
Intervention: Articaine (40 mL of articaine HCI 20 mg/mL with 2 mL isotonic sodium chloride solution)
Number of subjects: 50
Study 21401351 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine-fentanyl (40 mL of articaine HCI 20 mg/mL with 2 mL (100 µg) of fentanyl)
Number of subjects: 50
Study 18368615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg nocte for 2 days, 30 mg nocte for 12 days)
Number of subjects: 31
Study 18368615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16988084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored weight management intervention (6 monthly outpatient visits, 15 minutes each)
Number of subjects: 144
Study 16988084 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 144
Study 14523770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 61
Study 14523770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential GM‐CSF/bFGF therapy
Number of subjects: 0
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF alone
Number of subjects: 0
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF/bFGF group
Number of subjects: 0
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 0
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 0
Study 10749622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10749622 — intervention group
Group type: EXPERIMENTAL
Intervention: Any cytokine treatment
Number of subjects: 0
Study 9361572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin
Number of subjects: 433
Study 9361572 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin
Number of subjects: 433
Study 9361572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin for 10 days
Number of subjects: 433
Study 9361572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin for 5 days
Number of subjects: 433
Study 9361572 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 433
Study 9361572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of continuous intravenous heparin
Number of subjects: 433
Study 1551505 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol-240
Number of subjects: 40
Study 1551505 — intervention group
Group type: COMPARATOR
Intervention: iohexol-300
Number of subjects: 40
Study 4037710 — intervention group
Group type: EXPERIMENTAL
Intervention: Primperan (30 mg per day for 15 days)
Number of subjects: 0
Study 4037710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31210557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) for 3 months
Number of subjects: 64
Study 31210557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LGG)
Number of subjects: 64
Study 29189318 — intervention group
Group type: EXPERIMENTAL
Intervention: NANCAL-guided remifentanil administration
Number of subjects: 48
Study 29189318 — intervention group
Group type: COMPARATOR
Intervention: Fixed remifentanil concentration at 4 ng/ml
Number of subjects: 48
Study 29189318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure response to NANCAL
Number of subjects: 48
Study 26449721 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 66
Study 26449721 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg amphetamine
Number of subjects: 66
Study 26449721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26449721 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (various doses) in mice
Number of subjects: 66
Study 26449721 — intervention group
Group type: COMPARATOR
Intervention: Vehicle in mice
Number of subjects: 66
Study 24602062 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 433
Study 24602062 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory follow-up (Control)
Number of subjects: 433
Study 22729167 — intervention group
Group type: EXPERIMENTAL
Intervention: Blephasteam eyelid‐warming device
Number of subjects: 20
Study 22729167 — intervention group
Group type: COMPARATOR
Intervention: Warm compresses
Number of subjects: 20
Study 20145560 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi-bar exercise
Number of subjects: 9
Study 20145560 — intervention group
Group type: COMPARATOR
Intervention: Sham-bar exercise
Number of subjects: 9
Study 18203890 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG group (intake of 3 eggs per day, 640 mg/d additional dietary cholesterol)
Number of subjects: 28
Study 18203890 — intervention group
Group type: COMPARATOR
Intervention: SUB group (equivalent amount of egg substitute, 0 dietary cholesterol)
Number of subjects: 28
Study 18203890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 16434933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics prescribed (63.0% of patients)
Number of subjects: 1861
Study 16434933 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic neuroleptics prescribed (49.7% of patients)
Number of subjects: 1861
Study 16434933 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of neuroleptics (22.0% of patients)
Number of subjects: 1861
Study 16434933 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (28.0%) and risperidone (18.6%)
Number of subjects: 1861
Study 16434933 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one neuroleptic treatment change (44.9% in public, 39.2% in private)
Number of subjects: 1861
Study 12588387 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment
Number of subjects: 75
Study 12588387 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 microg g(-1) ointment
Number of subjects: 75
Study 10735152 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel iso-osmotic laxative
Number of subjects: 0
Study 8671231 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) of gonadotrophin-releasing hormone agonist (GnRHa) with a single injection of 3.75 mg Decapeptyl followed by daily s.c. administration of 0.1 mg Decapeptyl for at least 2 weeks prior to ovarian stimulation.
Number of subjects: 80
Study 8671231 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (LP) of gonadotrophin-releasing hormone agonist (GnRHa) with daily s.c. administration of 0.1 mg Decapeptyl initiated from the mid-luteal phase of the preceding cycle.
Number of subjects: 80
Study 8671231 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) in patients with stage III or IV endometriosis.
Number of subjects: 80
Study 8671231 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (LP) in patients with stage III or IV endometriosis.
Number of subjects: 80
Study 8671231 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) in patients with stage I or II endometriosis.
Number of subjects: 80
Study 8671231 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (LP) in patients with stage I or II endometriosis.
Number of subjects: 80
Study 2003660 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laceration repair with music
Number of subjects: 38
Study 2003660 — intervention group
Group type: COMPARATOR
Intervention: Standard laceration repair without music (control)
Number of subjects: 38
Study 6431075 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered 0.4 mg nitroglycerin spray
Number of subjects: 0
Study 6431075 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule containing 0.8 mg nitroglycerin solution
Number of subjects: 0
Study 6431075 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin tablet
Number of subjects: 0
Study 6431075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31706331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10^8 CFU, 5 drops once daily)
Number of subjects: 114
Study 31706331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 114
Study 27858723 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 12
Study 27858723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment (PA) program
Number of subjects: 49
Study 26563246 — intervention group
Group type: COMPARATOR
Intervention: Usual strategy 'case discussion'
Number of subjects: 49
Study 23514080 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sexual sensation seeking
Number of subjects: 715
Study 21558772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 160
Study 21558772 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study 19299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene continued for 8 years (RLX-C, n = 2280)
Number of subjects: 3967
Study 19299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene discontinued after 4 years (RLX-D, n = 401)
Number of subjects: 3967
Study 19299240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1286)
Number of subjects: 3967
Study 17540083 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling messages delivered immediately after consultation
Number of subjects: 55
Study 17540083 — intervention group
Group type: COMPARATOR
Intervention: Counselling messages delivered one day after consultation
Number of subjects: 55
Study 15462490 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 12
Study 15462490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15669595 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.025 IU/kg/day for 1 week, increasing to 0.05 IU/kg/day for 8 weeks
Number of subjects: 35
Study 15669595 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 35
Study 15669595 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 15669595 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with normal CRP levels
Number of subjects: 35
Study 15669595 — intervention group
Group type: COMPARATOR
Intervention: placebo with normal CRP levels
Number of subjects: 35
Study 10516940 — intervention group
Group type: EXPERIMENTAL
Intervention: Psiquial (fluoxetine formulation)
Number of subjects: 24
Study 10516940 — intervention group
Group type: COMPARATOR
Intervention: Prozac (fluoxetine formulation)
Number of subjects: 24